Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg , and 40 mg doses. - ASC30 oral once-daily tablet also...

SKYWORTH Unveils Revolutionary OmniView Matte Screen, Pushing MiniLED Displays to OLED-Level Performance

SKYWORTH Unveils Revolutionary OmniView Matte Screen, Pushing MiniLED Displays to OLED-Level Performance

SHENZHEN, China, April 22, 2025 /PRNewswire/ -- From April 15 to 19, 2025, SKYWORTH once again took center stage at the 137th China Import and Export Fair (Canton Fair), showcasing its latest breakthroughs in consumer electronics and setting new...

Inspur Communications Information Debuts at the 2025 Hong Kong InnoEX, Empowering the Digital Future

Inspur Communications Information Debuts at the 2025 Hong Kong InnoEX, Empowering the Digital Future

JINAN, China, April 18, 2025 /PRNewswire/ -- The 2025 Hong Kong International Innovation and Technology Exhibition (InnoEX) was grandly held in Hong Kong from April 13 to 16, with the theme "Innovation, Smart Mobility, Taking Off." Inspur...

Caliway Selected to Present CBL-514 Phase 2 Study Results for Dercum's Disease at World Orphan Drug Congress USA 2025

Caliway Selected to Present CBL-514 Phase 2 Study Results for Dercum's Disease at World Orphan Drug Congress USA 2025

CBL-514, Caliway's novel small molecule drug, was selected for data presentation at the World Orphan Drug Congress USA 2025, highlighting its promising Phase 2 study results (CBL-0201DD) for Dercum's Disease Treatment. The Phase 2 topline results...

Dyna.Ai Unveils Agentic AI Suite - The World's First Multi-Language, Multi-Channel, Multi-Modal AI Agent Platform for Enterprise

Dyna.Ai Unveils Agentic AI Suite - The World's First Multi-Language, Multi-Channel, Multi-Modal AI Agent Platform for Enterprise

SINGAPORE, April 17, 2025 /PRNewswire/ -- Dyna.Ai today announces the global launch of Agentic AI Suite, an enterprise-grade AI platform purpose-built for intelligent, collaborative agents that communicate across multi-language, multi-channel, and...

Montavista lithium metal battery product reaches above 1280 cycles using eVTOL flight profile

Montavista lithium metal battery product reaches above 1280 cycles using eVTOL flight profile

FRIEDRICHSHAFEN, Germany, April 14, 2025 /PRNewswire/ -- During the 31st AERO Friedrichshafen aviation exhibition in Germany, Montavista Energy Technologies Corporation (Anhui) (referred to as "Montavista") unveiled the latest cycling performance...

XCMG Crane Showcases Six European-Tailored Models at bauma 2025, Secures Bulk Orders with Sustainable Innovation

XCMG Crane Showcases Six European-Tailored Models at bauma 2025, Secures Bulk Orders with Sustainable Innovation

MUNICH, April 12, 2025 /PRNewswire/ -- At bauma 2025, the world's leading construction machinery trade fair, XCMG Crane made a resounding statement about its commitment to the European market by unveiling six cutting-edge crane models, engineered...

Tianneng Explores Future Possibilities in Power Battery Market with Technological Breakthroughs

Tianneng Explores Future Possibilities in Power Battery Market with Technological Breakthroughs

HUZHOU, China, April 8, 2025 /PRNewswire/ -- As a leader in the power battery industry, Tianneng continues to drive innovation in the battery market through relentless technological advancement and transformative business models. At a recent spring...

Spotlight on STAR Market Amid Tech-driven Rise in China

Spotlight on STAR Market Amid Tech-driven Rise in China

GUANGZHOU, China, April 2, 2025 /PRNewswire/ -- As of March 31, China's technology sector has demonstrated exceptional resilience and growth, underscored by the strong performance of key indices such as the STAR AI Index and the STAR Growth Index,...

Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

SAN FRANCISCO and SUZHOU, China, March 31, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • menu
    menu